Individualized Intervention Guided by BCR-ABL Transcript Levels after HLA-Identical Sibling Donor Transplantation Improves HSCT Outcomes for Patients with Chronic Myeloid Leukemia

Abstract

Listen

Translate article

The aim of this study was to determine the effect of individualized intervention guided by BCR-ABL transcript levels after hematopoietic stem cell transplantation (HSCT) on relapse and leukemia-free survival (LFS) of patients with chronic myelogenous leukemia (CML). Eighty-four consecutive patients who received HLA-identical sibling HSCT were enrolled. The patients were conditioned with a modified busulfan and cyclophosphamide regimen, and received stem cells from a HLA-identical sibling donor. Patients were identified as high risk of relapse based on serial monitoring of post-HSCT BCR-ABL transcript levels, and patients in the high-risk group were given individualized intervention. Interventions included immunosuppressant withdrawal, modified donor lymphocyte infusion, and imatinib mesylate. Engraftment was successful in all patients. Twenty-eight patients were categorized as high risk because of higher post-HSCT BCR-ABL transcript levels and received intervention. The 56 low-risk patients received no intervention. Twenty-five high-risk patients achieved complete molecular remission at a median of 49 days (range: 18-232 days) after intervention. Two high-risk patients and 1 low-risk patient ultimately relapsed, the 4-year relapse rate was 3.9% ± 4.4%. Overall 4-year survival was 89.0% ± 7% and the 4-year LFS was 89.2% ± 6.8%. All surviving patients remains in complete molecular remission after a median of 1481 (1040-1794) days follow-up. Individualized intervention based on the post-HSCT BCR-ABL transcript level can decrease relapse and increase LFS of patients with CML after HLA-identical sibling HSCT.